EZH2-Targeted Therapies in Cancer: Hype or a Reality
Marie-Lisa Eich1, Mohammad Athar2, James E Ferguson3
1Institute of Pathology, University Hospital Cologne, Cologne, Germany.
Abstract:
Next-generation genomic sequencing has identified multiple novel molecular alterations in cancer. Since the identification of DNA methylation and histone modification, it has become evident that genes encoding epigenetic modifiers that locally and globally regulate gene expression play a crucial role in normal development and cancer progression. The histone methyltransferase enhancer of zeste homolog 2 (EZH2) is the enzymatic catalytic subunit of the polycomb-repressive complex 2 (PRC2) that can alter gene expression by trimethylating lysine 27 on histone 3 (H3K27). EZH2 is involved in global transcriptional repression, mainly targeting tumor-suppressor genes. EZH2 is commonly overexpressed in cancer and shows activating mutations in subtypes of lymphoma. Extensive studies have uncovered an important role for EZH2 in cancer progression and have suggested that it may be a useful therapeutic target. In addition, tumors harboring mutations in other epigenetic genes such as ARID1A, KDM6, and BAP1 are highly sensitive to EZH2 inhibition, thus increasing its potential as a therapeutic target. Recent studies also suggest that inhibition of EZH2 enhances the response to tumor immunotherapy. Many small-molecule inhibitors have been developed to target EZH2 or the PRC2 complex, with some of these inhibitors now in early clinical trials reporting clinical responses with acceptable tolerability. In this review, we highlight the recent advances in targeting EZH2, its successes, and potential limitations, and we discuss the future directions of this therapeutic subclass.
Insights
Enhancer of zeste homolog 2 (EZH2) is a key epigenetic regulator overexpressed in many cancers. Inhibiting EZH2 shows promise as a therapeutic strategy, enhancing immunotherapy response and sensitivity in tumors with specific mutations.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Epigenetic modifiers, including DNA methylation and histone modification, are crucial in cancer development.
- Enhancer of zeste homolog 2 (EZH2), a component of the polycomb-repressive complex 2 (PRC2), regulates gene expression via histone H3 lysine 27 trimethylation (H3K27).
- EZH2 overexpression and activating mutations are observed in various cancers, particularly lymphomas, and it targets tumor-suppressor genes.
Purpose of the Study:
- To review recent advancements in targeting EZH2 as a therapeutic strategy in cancer.
- To discuss the successes, limitations, and future directions of EZH2 inhibition in cancer treatment.
- To explore the potential of EZH2 inhibitors in combination with other therapies, such as immunotherapy.
Main Methods:
- Literature review of studies on EZH2 function, expression, and therapeutic targeting in cancer.
- Analysis of clinical trial data for EZH2 inhibitors.
- Examination of preclinical studies investigating EZH2 inhibition in various cancer models and its impact on immunotherapy response.
Main Results:
- EZH2 plays a significant role in cancer progression and is a validated therapeutic target.
- Tumors with mutations in epigenetic genes like ARID1A, KDM6, and BAP1 exhibit heightened sensitivity to EZH2 inhibition.
- Early clinical trials of EZH2 inhibitors have demonstrated clinical responses and acceptable tolerability.
- Inhibition of EZH2 has been shown to potentiate anti-tumor immune responses.
Conclusions:
- Targeting EZH2 represents a promising therapeutic avenue in oncology, with several small-molecule inhibitors in clinical development.
- EZH2 inhibition offers potential benefits beyond direct anti-tumor effects, including enhanced immunotherapy efficacy and targeting of specific genetic vulnerabilities.
- Further research is warranted to optimize EZH2-targeted therapies, overcome resistance mechanisms, and fully elucidate their role in combination treatment strategies.
More Related Videos
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
09:12Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
Published on: June 14, 2024
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
02:38Mitogens and the Cell Cycle